Table 1.
Demographic and disease characteristics
| (n = 599) | |
|---|---|
| Agea (years) | 56.81 (10.84) |
| Disease durationb (years) | 12 (20-6) |
| Sex,a F (%) | 457 (76.29) |
| CRP at baseline, median (IQR) mg/Lb | 34 (17-63) |
| ESR at baseline, median (IQR) mg/Lb | 43 (27-68) |
| DAS28 at baselinea | 6.36 (0.90) |
| Change in DAS28a | -2.01 (1.23) |
| Concurrent DMARD n (%) | 449 (74.96) |
| Infliximab | 272 (45.41) |
| Etanercept | 220 (36.73) |
| Adalimumab | 107 (17.86) |
CRP, C-reactive protein; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; F, female; IQR, interquartile range; SD, standard deviation. aValues are expressed as mean (SD). bValues are expressed as median (IQR). All other values are n (%). Disease duration was measured in 598 patients; erythrocyte sedimentation rate (ESR) levels were measured in 578 patients; and change in DAS28 was measured in 442 patients.